Gritstone's Phase 2 cancer vaccine trial misses the mark, stock spirals down
2024-04-02
临床2期疫苗
Gritstone bio’s stock took a tumble in premarket trading Tuesday morning following mixed data from a Phase 2 study of its cancer vaccine, but it’s still moving ahead with a public offering of its stock and Phase 3 planning.
In a late Monday release, Gritstone touted the data as positive from the Phase 2 portion of its Phase 2/3 GRANITE trial of its neoantigen cancer vaccine in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). Progression-free survival favored Gritstone’s vaccine in an early trend, even though the dataset is “immature,” the company said in its presentation.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。